Objective To evalucate in vitro activity of cefcapene against clinical isolated pathogenic bacteria in recent three years in China.Methods The clinical isolates were collected and the minimal inhibitory concentrations(MICs)were determined by the microbroth dilution method.Results A total of 308 pathogenic bacteria over the period 2021-2023 were studied.Cefcapene exhibited excellent antibacterial activity against Streptococci and methicillin susceptible Staphylococcus aureus(MSSA),which was similar to penicillin and cefpodoxime,and better than cefuroxime,cefaclor and cefixime.Against gram-negative bacteria,cefcapene also showed better antibacterial activity,especially against non-extended spectrum β-lactamases(ESBLs)Escherichia coli,Haemophilus influenzae and Moraxella catarrhalis,were comparable to cefixime and cefpodoxime,better than cefuroxime and cefaclor.Conclusion Cefcapene showed excellent antibacterial activity against clinical isolates from community-acquired pneumonia,include streptococcus pneumonia,MSSA,Haemophilus influenzae and Moraxella catarrhalis in recent years in China,which identical with those reported in literature ten years ago in China and foreign.It is a highly effective oral cephalosporin suitable for adults and children with respiratory tract infection,otitis media,sinusitis,urinary tract infection and other outpatient infections.
国家科技期刊平台
NSTL
万方数据
